Loading…
Zyprexa Relprevv·Psychiatry - Depot Antipsychotics
Maintenance treatment of Schizophrenia
No source link confirmed for this record yet. Its own source notes are under Additional.
Max Dose
300 mg Q2W
Half-life
30 Days
High risk: PDSS Risk
CRITICAL
Caution: Monitoring
3 HOURS
Avoid / Cautions
Unmonitored administration environments. Severe CNS depression. Acute narrow-angle glaucoma. Pregnancy Category C.
Overview
A depot formulation of Olanzapine. Exceptional efficacy, but restricted by one of the most intense and dangerous post-injection monitoring protocols in modern psychiatry.
Clinical Focus
Can cause Post-Injection Delirium/Sedation Syndrome (PDSS), where the drug accidentally hits a blood vessel, inducing a sudden, profound coma.
Bottom Line
Olanzapine pamoate LAI is a long-acting injectable olanzapine for treatment-resistant schizophrenia, but carries unique post-injection delirium/sedation syndrome (PDSS) requiring 3-hour observation.
Brand Names
Zyprexa Relprevv
Parenteral
Powder for reconstitution. Forms a thick yellow suspension.
Prescribing & PBS
Authority Required (PBS). Must be administered in a registered healthcare facility with resuscitation equipment.
Primary
Maintenance treatment of Schizophrenia.
Clinical Place
Reserved for severely non-compliant patients who respond brilliantly to oral olanzapine but fail on other depots. The strict monitoring limits its use in the community.
No calculator, monitoring schedule or factsheet is linked to this medicine page yet.